Estazolam

CHEMBL285674 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

294.7 g/mol

LogP

1.7

Phase

4

This benzodiazepine medication works by enhancing the calming effects of GABA in the brain to help with falling and staying asleep. It is used for the short-term treatment of insomnia.

Peso Molecular

294,7400 g/mol

LogP

1,70

TPSA

43,10 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Insomnia Breast Cancer Prostate Cancer Colorectal Cancer

Mecanismo de Ação

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2

InChI

InChI=1S/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2

Molecular Formula

C16H11ClN4

HBD / HBA

- / 3

Ligações Rotacionáveis

1

Átomos Pesados

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This benzodiazepine medication works by enhancing the calming effects of GABA in the brain to help with falling and staying asleep. It is used for the short-term treatment of insomnia.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Estazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL285674. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3261. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Estazolam no PillFYI

Estrutura

Dados Rápidos

Fórmula: C16H11ClN4

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.